Usefulness of vonoprazan,a potassium ion-competitive acid blocker,for primary eradication of Helicobacter pylori

被引:8
|
作者
Shinya Yamada [1 ]
Takumi Kawakami [1 ]
Yoshikazu Nakatsugawa [1 ]
Takahiro Suzuki [1 ]
Hideki Fujii [1 ]
Naoya Tomatsuri [1 ]
Hideki Nakamura [1 ]
Hideki Sato [1 ]
Yusuke Okuyama [1 ]
Hiroyuki Kimura [1 ]
Norimasa Yoshida [1 ]
机构
[1] Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital
关键词
Helicobacter pylori; Eradication; Vonoprazan; Chronic gastritis; Potassium ion-competitive acid blocker;
D O I
暂无
中图分类号
R573 [胃疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To investigate usefulness of triple therapy with vonoprazan,a potassium ion-competitive acid blocker and antibiotics,for Helicobacter pylori(H.pylori) eradication.METHODS The H.pylori eradication rate was examined in 2507 patients(2055 undergoing primary eradication and 452 undergoing secondary eradication,excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015.For patients treated from March 2013 to February 2015,a proton pump inhibitor(PPI) was used to reduce acid secretion,while vonoprazan was used after March 2015.The success rates of the 2 regimens(PPI + amoxicillin + clarithromycin/metronidazole,or vonoprazan + amoxicillin + clarithromycin/metronidazole) were compared.RESULTS The success rate of primary H.pylori eradication was significantly higher in the vonoprazan group.When stratified by the underlying disease,a significant increase of the H.pylori eradication rate was observed in patients with chronic gastritis.A significantly lower H.pylori eradication rate was observed in younger patients compared to older patients in the PPI group,but there was no difference according to age in the vonoprazan group.On the otherhand,the success rate of secondary eradication was similar at approximately 90% in both groups.CONCLUSION Vonoprazan is very useful for primary eradication of H.pylori,and may become a first-line acid secretion inhibitor instead of PPIs.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 50 条
  • [21] Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
    Duzenli, Tolga
    Koseoglu, Huseyin
    Kaya, Muhammed
    Sezikli, Mesut
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (04): : 435 - 435
  • [22] Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients
    Takimoto, Mayu
    Tomita, Toshihiko
    Yamasaki, Takahisa
    Fukui, Shota
    Taki, Masato
    Okugawa, Takuya
    Kondo, Takashi
    Kono, Tomoaki
    Tozawa, Katsuyuki
    Arai, Eitatsu
    Ohda, Yoshio
    Oshima, Tadayuki
    Fukui, Hirokazu
    Watari, Jiro
    Miwa, Hiroto
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (03) : 739 - 745
  • [23] Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy
    Ozaki, Haruhiko
    Harada, Satoshi
    Takeuchi, Toshihisa
    Kawaguchi, Shinpei
    Takahashi, Yoshiaki
    Kojima, Yuichi
    Ota, Kazuhiro
    Hongo, Yasushi
    Ashida, Kiyoshi
    Sakaguchi, Masahiro
    Tokioka, Satoshi
    Sakamoto, Hiroki
    Furuta, Takahisa
    Tominaga, Kazunari
    Higuchi, Kazuhide
    DIGESTION, 2018, 97 (03) : 212 - 218
  • [24] Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients
    Mayu Takimoto
    Toshihiko Tomita
    Takahisa Yamasaki
    Shota Fukui
    Masato Taki
    Takuya Okugawa
    Takashi Kondo
    Tomoaki Kono
    Katsuyuki Tozawa
    Eitatsu Arai
    Yoshio Ohda
    Tadayuki Oshima
    Hirokazu Fukui
    Jiro Watari
    Hiroto Miwa
    Digestive Diseases and Sciences, 2017, 62 : 739 - 745
  • [25] Vonoprazan a novel potassium competitive acid blocker; another leap forward
    Elsabaawy, Maha
    Shaban, Ahmed
    Al-Arab, Ahmed Ezz
    Elbahr, Osama
    Edrees, Ahmed
    Afify, Sameh
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2024, 19 (02): : 135 - 142
  • [26] THE EFFECT OF FOOD ON THE PHARMACOKINECTICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN
    Jenkins, Helen
    Leifke, Eckhard
    Mulford, Darcy
    Hibberd, Mark
    Howden, Colin W.
    GASTROENTEROLOGY, 2021, 160 (06) : S446 - S447
  • [27] The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
    Mulford, Darcy J.
    Leifke, Eckhard
    Hibberd, Mark
    Howden, Colin W.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (02): : 278 - 284
  • [28] Potassium-Competitive Acid Blocker Antisecretory Therapy Improves H. pylori Eradication
    Matsumoto, Hiroshi
    Kamada, Tomoari
    Oosawa, Motoyasu
    Katsumata, Ryo
    Fujita, Minoru
    Nakato, Rui
    Murao, Takahisa
    Ishii, Manabu
    Kusunoki, Hiroaki
    Haruma, Ken
    Shiotani, Akiko
    GASTROENTEROLOGY, 2016, 150 (04) : S878 - S878
  • [29] Correction to: Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients
    Mayu Takimoto
    Toshihiko Tomita
    Takahisa Yamasaki
    Shota Fukui
    Masato Taki
    Takuya Okugawa
    Takashi Kondo
    Tomoaki Kono
    Katsuyuki Tozawa
    Eitatsu Arai
    Yoshio Ohda
    Tadayuki Oshima
    Hirokazu Fukui
    Jiro Watari
    Hiroto Miwa
    Digestive Diseases and Sciences, 2021, 66 : 2472 - 2472
  • [30] Ecofriendly chromatographic method for the separation and quantification of vonoprazan fumarate, a novel potassium competitive acid blocker with amoxicillin and clarithromycin which are effective in the treatment of Helicobacter pylori
    Ali, Noha A. M.
    El-Gindy, Alaa El-Din M. A.
    Wahba, Mary Elias Kamel
    Mostafaa, Aziza E.
    ACTA CHROMATOGRAPHICA, 2025,